论文部分内容阅读
目的观察阿托伐他汀治疗冠心病慢性心力衰竭预后的影响。方法将2007年1月至2008年10月院冠心病慢性心力衰竭患者127例,随机分成治疗组(65例),对照组(62例)。所有心力衰竭患者均常规治疗,治疗组在此基础上加用阿托伐他汀20 mg,1次/晚。治疗16周后复查血脂、C反应蛋白(CRP)、左室射血分数(LVEF)。观察所有患者的住院次数、总日数、病死率。结果治疗组与对照组比较,治疗16周后,治疗组血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、CRP均有显著降低,LVEF则有明显提高。治疗组住院次数和总日数比对照组减少,但差异无统计学意义(P>0.05);病死率明显降低,两组相比差异有统计学意义(P<0.05。结论阿托伐他汀能够改善冠心病慢性心力衰竭患者的预后。
Objective To observe the effect of atorvastatin on the prognosis of patients with chronic heart failure of coronary heart disease. Methods From January 2007 to October 2008, 127 patients with coronary heart disease and chronic heart failure were randomly divided into treatment group (65 cases) and control group (62 cases). All patients with conventional heart failure treatment, the treatment group on this basis with atorvastatin 20 mg, 1 / night. Blood lipid, C-reactive protein (CRP) and left ventricular ejection fraction (LVEF) were examined after 16 weeks of treatment. All patients were observed in the number of hospitalizations, the total number of days, mortality. Results After treatment for 16 weeks, the levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglyceride (TG) and CRP in the treatment group were significantly lower than those in the control group improve. The number of hospitalization and the total number of days in the treatment group decreased compared with the control group, but the difference was not statistically significant (P> 0.05); the mortality rate was significantly lower (P <0.05) .Conclusion Atorvastatin can improve Prognosis of patients with coronary heart disease and chronic heart failure.